Randomized clinical trial of hepatic resection versus radiofrequency ablation for early‐stage hepatocellular carcinoma. BJS 2017; 104: 1775-1784.
Published: 1st November 2017
Authors: K. K. C. Ng, K. S. H. Chok, A. C. Y. Chan, T. T. Cheung, T. C. L. Wong, J. Y. Y. Fung et al.
Hepatic resection and radiofrequency ablation (RFA) are treatment options for early‐stage hepatocellular carcinoma (HCC). Whether tumour recurrence and long‐term survival favour either treatment has not been established. This randomized trial aimed to test the hypothesis that RFA is superior to hepatic resection in terms of lower tumour recurrence rate and better long‐term survival.
Patients with early‐stage HCC (solitary tumour no larger than 5 cm; or no more than 3 tumours, each 3 cm or smaller) were randomized into hepatic resection and RFA groups. Demographic and clinical characteristics, and short‐ and long‐term outcome measures were compared between groups. Primary and secondary outcome measures were overall tumour recurrence and survival respectively.
Clinicopathological data were similar in the two groups, which each contained 109 patients. The RFA group had a shorter treatment duration, less blood loss and shorter hospital stay than the resection group. Mortality and morbidity rates were similar in the two groups. The overall tumour recurrence rate was similar in the resection and RFA groups (71·3
RFA for early‐stage HCC is not superior to hepatic resection, in terms of tumour recurrence, overall survival and disease‐free survival. Registration number: HKUCTR‐10 (
You may also be interested in
Authors: K. Mohkam, O. Farges, E. Vibert, O. Soubrane, R. Adam, F.‐R. Pruvot et al.
Notes: Multi‐institutionally validated prognostic tool
Authors: V. Wanjura, E. Szabo, J. Österberg, J. Ottosson, L. Enochsson, G. Sandblom et al.
Notes: Avoid unnecessary surgery
Authors: P. Probst, S. Ohmann, U. Klaiber, F. J. Hüttner, A. T. Billeter, A. Ulrich et al.
Notes: Publication bias likely
Randomized clinical trial
Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection. BJS 2017; 104: 1462-1469.
Authors: S. B. Ellebæk, C. W. Fristrup, C. Hovendal, N. Qvist, L. Bundgaard, S. Salomon et al.
Notes: No additional benefit
Randomized clinical trial
Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. BJS 2017; 104: 1443-1450.
Authors: C. Palanivelu, P. Senthilnathan, S. C. Sabnis, N. S. Babu, S. Srivatsan Gurumurthy, N. Anand Vijai et al.
Notes: Shorter stay
Authors: K. J. Roberts
Authors: B. Le Roy, M. Gelli, G. Pittau, M.‐A. Allard, B. Pereira, B. Serji et al.
Notes: Option to increase resectability
Authors: A. J. Klompenhouwer, M. E. E. Bröker, M. G. J. Thomeer, M. P. Gaspersz, R. A. de Man, J. N. M. IJzermans et al.
Notes: Wait and see policy justified
Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. BJS 2017; 104: 1568-1577.
Authors: L. G. M. van der Geest, V. E. P. P. Lemmens, I. H. J. T. de Hingh, C. J. H. M. van Laarhoven, T. L. Bollen, C. Y. Nio et al.
Notes: Negative impacts
Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. BJS 2017; 104: 1539-1548.
Authors: R. Ravikumar, C. Sabin, M. Abu Hilal, A. Al‐Hilli, S. Aroori, G. Bond‐Smith et al.
Notes: No difference between type of reconstruction
Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. BJS 2017; 104: 1558-1567.
Authors: D. Kleive, M. A. Sahakyan, A. E. Berstad, C. S. Verbeke, I. P. Gladhaug, B. Edwin et al.
Notes: Severe complications, more reoperations